GlaxoSmithKline undeterred by spotty results for Relovair

GlaxoSmithKline ($GSK) is pushing ahead with its plan to submit Relovair to regulators for approval this year, despite more mixed results in clinical trial data released Friday. The one-time-a-day inhaled medication for chronic lung disease was found to be better than the twice-daily drug Advair in only one of two trials. Other trials have produced similarly mixed results. Still, the company thinks a once-daily treatment will have a market and that regulators will approve it. Story | More